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Background. Skin and soft tissue infections are common reasons for medical care. Use of broad-spectrum therapy and costs
have increased. Assessment of early treatment response has been given a central role both in clinical trials and everyday practice.
However, there is a paucity of data on the dynamics of response, causes of early nonresponse, and how early nonresponse affects
resource use and predicts outcome.
Methods. We prospectively enrolled 216 patients hospitalized with cellulitis. Clinical and biochemical response data during the
first 3 days of treatment were analyzed in relation to baseline factors, antibiotic use, surgery, and outcome. Multivariable analysis
included logistic lasso regression.
Results. Clinical or biochemical response was observed in the majority of patients the day after treatment initiation. Concor-
dance between clinical and biochemical response was strongest at days 2 and 3. Female sex, cardiovascular disease, higher body
mass index, shorter duration of symptoms, and cellulitis other than typical erysipelas were predictors of nonresponse at day 3. In
contrast, baseline factors were not predictive of clinical failure assessed posttreatment. Among cases with antibiotic treatment esca-
lation by day 2, 90% (37/41) had nonresponse at day 1, but only 5% (2/40) had inappropriate initial therapy. Nonresponse at day 3
was a predictor of treatment duration >14 days, but not of clinical failure.
Conclusions. Nonpharmacological factors had a major impact on early response dynamics. Delayed response was rarely related
to inappropriate therapy but strongly predictive of early treatment escalation, suggesting that broadening antibiotic treatment may
often be premature.
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Skin and soft tissue infections (SSTIs) are common causes of
medical care, and increasing frequency and costs are reported
[1–3]. The SSTI that most often requires systemic antibiotics
is cellulitis, a diffuse skin infection that includes the superficial
subtype known as erysipelas [4]. Cellulitis is usually caused by
β-hemolytic streptococci (BHS) that are susceptible to penicillin
and other narrow-spectrum antibiotics [4]. However, there are
significant treatment challenges, including overuse of broad-
spectrum and intravenous antibiotics [5, 6], difficulties regard-
ing when to initiate rescue therapy and when to stop treatment
[7], and frequent recurrences [8]. Toxin effects and profound
local inflammation, not necessarily corresponding to bacterial
burden or antibiotic needs, may contribute to these problems
[7, 9]. Also, host factors affecting the dynamics of treatment
response may adversely impact antibiotic choices and other
resource use.
Increasing the knowledge on the clinical course, response
dynamics, and associated factors may be important in dealing
with the challenges of cellulitis care. Optimizing the assessment
of treatment response may be a key factor, due to its major role
in treatment decisions and clinical trials. The standard assess-
ment of response in SSTI trials has been performed after end
of treatment (EOT). However, clinical success posttreatment
may often be the result of natural improvement, as demonstrat-
ed by high cure rates following nonantibiotic therapy in studies
from the preantibiotic and early antibiotic eras [10]. Moreover,
2 studies published in 1937 comparing antibiotic and ultraviolet
therapy found the difference between treatment arms to peak
2–3 days after start of treatment, suggesting that early response
is a more treatment-specific measure than cure assessed post-
treatment [11, 12]. Clinical response 48–72 hours after treat-
ment initiation is therefore currently recommended by the US
Food and Drug Administration (FDA) as the primary efficacy
endpoint for clinical trials [13]. This has not been without con-
troversy, however, primarily because early response is not the
ultimate goal of antibiotic therapy [14]. European guidelines
still recommend cure assessed after treatment as the primary
endpoint [15].
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The aim of this study was first to describe the early and late
course after treatment initiation, including how rapidly the clin-
ical and biochemical responses occur. Second, we wanted to ex-
amine early response dynamics in relation to underlying factors,
etiology, and severity as well as antibiotic escalation and other
outcomes. By limiting the study to cellulitis in a setting with low
prevalence of BHS and Staphylococcus aureus resistant to first-
line antibiotics [16], the study of early response in relation to
baseline factors could be performed largely without influence
of confounders such as need of surgical drainage or antibiotic
resistance. The results may provide an improved basis for the
assessment of early response and how initial response can be
used in guiding continued treatment and predicting outcome.
PATIENTS AND METHODS
Study Population
The study population has been described previously [17]. In
brief, patients (aged ≥18 years) with acute cellulitis admitted
to Haukeland University Hospital (Bergen, Norway) were pro-
spectively included. Patients with drainable collections of pus or
other fluid were excluded.
Clinical Characteristics and Response
Data on underlying factors and clinical findings at admission
were obtained by detailed history and clinical examination.
Clinical evaluation of response after initiation of intravenous
treatment at admission was performed daily until improvement
or discharge from hospital; local inflammation intensity and
spread of erythema and, in a subset of patients, the area of er-
ythema (length times width) were registered. In addition, blood
for measurement of leukocytes and C-reactive protein (CRP)
was obtained daily until a reduction of at least 20% in 1 day
was observed or the patient was discharged from hospital. A
telephone consultation scheduled at approximately 2 weeks
after cessation of therapy was used to register residual inflam-
mation and increase in symptoms or new course of antibiotics
posttreatment. Criteria for response and failure were defined as
follows:
• Response at day 1: cessation of lesion spread and overall im-
provement of local inflammation (intensity of erythema, warmth,
and tenderness) at the day 1 assessment compared to admission.
• Nonresponse at day 1: criteria for response day 1 not met.
• Response at day 3 (“early response”): local response (cessa-
tion of lesion spread and overall improvement of local inflam-
mation) plus CRP reduction of ≥20% by day 3, that is, at day 1
compared to admission, day 2 compared to day 1, and/or at day
3 compared to day 2.
• Nonresponse at day 3: criteria for response day 3 not met.
• Indeterminate response at day 1 or day 3: ≥1 response
variable missing.
• Clinical failure posttreatment: increase in symptoms or
new course of antibiotics between end of therapy and 2 weeks
after EOT, or death or readmission for SSTI within 30 days of
discharge.
• Clinical cure posttreatment: absence of clinical failure
posttreatment.
• Indeterminate outcome posttreatment: loss to follow-up or
≥1 posttreatment outcome variable missing.
Bacterial Etiology and Treatment
Bacterial culture and serological analyses were performed as
described previously [17]. Confirmed BHS etiology was de-
fined by streptococcal seropositivity according to specific cri-
teria and/or growth of BHS in culture of blood or normally
sterile tissue [18]. Probable BHS etiology was defined as
BHS in cutaneous swabs or a satisfactory response to penicillin
monotherapy, defined as clinical response at EOT in patients
receiving no other antibiotics during the course. Cases lacking
both 2 serology samples and a positive culture of blood or nor-
mally sterile tissue were considered nonevaluable regarding
BHS etiology. Discordant or inappropriate treatment was de-
fined as penicillin monotherapy as initial treatment in cases
without confirmed or probable BHS etiology. Antibiotic treat-
ment escalation was defined as addition of an antimicrobial
agent or other change resulting in a regimen with broader
antimicrobial spectrum. Surgical treatment escalation was
defined as a first or more extensive surgery than performed
before >1 day after start of treatment.
Statistical Analysis
Categorical data were analyzed using the χ2 or Fisher exact test.
Continuous data were compared using the Mann–Whitney U
test. All reported statistical tests are 2-sided, and P values <.05
are considered statistically significant. For multivariable analy-
ses, a logistic lasso regression model was used, due to a high
number of predictors compared with the number of events/
nonevents, and the risk of severe overfitting when using ordi-
nary logistic models [19]. Lasso regression is a shrinkage meth-
od, and the coefficient estimates of predictors with little or no
predictive value will be shrunk to zero (an odds ratio of 1).
For comparison, we report results from normal univariate and
adjusted logistic regression. For the latter model, we also report
tests of the joint effect of all predictors, which tests if the pre-
dictors jointly have any predictive power. To evaluate the dis-
criminative ability of the lasso model, we used leave-pair-out
cross-validation of the entire model fitting procedure to esti-
mate the area under the receiver operating characteristic curve
(AUC/C-statistic) [20]. Details concerning the statistical meth-
ods, including regression methods and selection of predictors,
are provided in the Supplementary Methods.
RESULTS
Patients, Bacterial Etiology, and Antibiotic Treatment
Two hundred sixteen patients were included. Clinical character-
istics and bacterial etiology have been published elsewhere [17].










In brief, median age was 54.5 years (range, 18–94 years), and
57% had lower extremity infection. Of 203 patients evaluable
for assessment of BHS etiology, 72% had confirmed BHS, and
an additional 13% had probable BHS infection. No cases with
methicillin-resistant S. aureus were detected.
Dynamics and Concordance of Different Early Clinical and Biochemical
Response Parameters
At day 1, 55% of evaluable cases (116/211) had cessation of
lesion spread, and 52% (109/211) had improvement of local in-
flammation (Figure 1A), but 16% (34/211) had cessation only,
and 13% (27/211) had improvement of inflammation only.
Local clinical response defined by a combination of these 2
events was seen in 39% (82/212). Local clinical response or bio-
chemical response was observed at day 1 in 74% (148/200) of
cases (Figure 1B).
Concordance between different clinical measures and bio-
chemical response was strongest at day 2 and 3 (Supplemen-
tary Table 1). In a subgroup of 57 patients, reduction of lesion
size was measured but had a weaker association with bio-
chemical response compared with other clinical response
parameters.
An overall early response according to defined criteria—that
is, local clinical response plus CRP response by day 3—was
observed in 90% (170/190).
Figure 1. Clinical and biochemical response at days 1, 2, and 3. Response evaluation was based on comparison with findings the day before. Response at days 2 and 3 was
defined as response by day 2 and 3, respectively. See the “Methods” section for further details. A, Different clinical and biochemical response parameters are presented. ΔBody
temperature ≤37.5°C in ≥2 separate measurements in 1 day (≥1 measurement if discharged) among cases with temperature >37.5°C the day before. TNot based on com-
parison with the day before but compared to the maximum value of all preceding days in hospital. B, Clinical and/or biochemical response using combined parameters. Clinical
response was defined as cessation of lesion spread and overall improvement of local inflammation from one day to the next. Biochemical response was defined as at least 20%
reduction of blood leukocytes or C-reactive protein (CRP) from one day to the next. The number of cases with indeterminate response (≥1 response parameter missing) at days 1,
2, and 3 were 16, 28, and 24, respectively. Abbreviations: Biochem+, biochemical response; Biochem-, no biochemical response; Clin+, clinical response; Clin-, no clinical
response.











More than half of the patients had residual signs of inflamma-
tion at EOT (Figure 2). The median duration of the recall period
(ie, the time from EOT to the telephone interview) was slightly
longer in the cases with residual inflammation at EOT (22 days
vs 20 days; P = .09). Signs of inflammation were still common at
the posttreatment evaluation (Figure 2). Among 112 cases with
residual inflammation at EOT, 18 (16%) had deterioration or re-
admission posttreatment (as in the definition of clinical failure),
compared with 2 of 79 (3%) cases without such residual inflam-
mation (odds ratio, 7.4 [95% confidence interval, 1.7–32.8];
P = .003). Clinical course data limited to the cases without dis-
cordant initial therapy showed a pattern equal to cases overall
(Supplementary Figure).
Factors Associated With Early Nonresponse and Failure Posttreatment
Univariate analyses of factors possibly associated to nonre-
sponse at days 1 and 3 are shown in Supplementary Table 2.
Only cases without evidence of initial discordant therapy were
entered into multivariable models to identify nonpharmacolog-
ical predictors of early nonresponse (see flowchart in Figure 3).
The adjusted lasso model identified no predictors of nonre-
sponse at day 1 (Table 1). Antibiotic therapy prior to admission
was not associated with decreased risk of nonresponse at day 1
Figure 2. Clinical course after treatment. Status at end of treatment and post-
treatment was determined by a telephone consultation scheduled approximately 2
weeks after cessation of therapy. Signs of residual inflammation (red/rose/purple
discoloration, tenderness, warmth) and deterioration (symptom increase or new an-
tibiotic course) after treatment were registered. Readmissions for skin and soft tis-
sue infection (SSTI) within 30 days are also shown. The number of cases with
indeterminate outcome (≥1 parameters missing) at end of treatment and posttreat-
ment were 25 and 15, respectively.
Figure 3. Flowchart of cases eligible for multivariable analyses to identify predictors of nonresponse at day 1 and day 3. Abbreviations: BMI, body mass index;
SIRS, systemic inflammatory response syndrome.










Table 1. Regression Models for Nonresponse at Days 1 and 3 Among Cases Without Initial Discordant Therapya
Characteristicb













ORc P Value ORc P Valued ORc ORc P Value ORc P Valuee ORc
Age (years) 0.99 .50 0.99 .29 1 1.02 .14 0.97 .27 1
Female sex 0.80 .46 0.89 .73 1 4.01 .01 5.10 .03 2.09
Cardiovascular disease 1.19 .56 1.46 .38 1 5.05 .002 10.70 .006 2.83
Diabetes mellitus 1.56 .32 1.39 .51 1 1.47 .59 0.65 .60 1
Previous local surgery/radiation 0.81 .56 0.88 .77 1 1.77 .30 1.84 .40 1
Previous local cellulitis 0.94 .86 1.08 .84 1 1.06 .92 0.84 .82 1
Chronic edema 0.91 .76 0.49 .13 1 1.83 .23 0.53 .50 1
BMI (kg/m²)f 1.04 .15 1.03 .36 1 1.08 .07 1.11 .08 1.03
Symptom duration (days)f 0.89 .17 0.90 .27 1 0.71 .03 0.79 .21 0.90
Prior antibiotic therapyb,g 0.55 .08 0.52 .10 1 1.17 .78 1.70 .48 1
Extremity infection 1.20 .57 1.30 .54 1 1.82 .34 1.57 .62 1
Typical erysipelash 1.60 .12 1.46 .24 1 0.40 .07 0.23 .02 0.53
Sepsis (≥2 SIRS criteria) 1.75 .06 1.52 .20 1 1.63 .33 2.08 .25 1
TBSA%f 1.04 .51 1.11 .29 1 0.95 .61 0.90 .52 1
Abbreviations: BMI, body mass index; OR, odds ratio; SIRS, systemic inflammatory response syndrome; TBSA%, percentage of total body surface area with erythema.
a Cases with initial penicillin monotherapy and either (1) streptococcal etiology not confirmed or probable or (2) streptococcal etiology nonevaluable were excluded from the analysis (in a total of
13 of 216 cases) see also Figure 3.
b At admission.
c OR values >1 indicate greater risk of nonresponse, and OR values <1 indicate greater probability of response.
d Test of joint effect of predictors at day 1: P = .34.
e Test of joint effect of predictors at day 3: P = .008.
f The predictors were winsorized as follows: BMI at 40 kg/m2, symptom duration at 6 days, and TBSA% at 10%.
g Oral antibiotic treatment was started the day before admission or earlier.
h Sharply demarcated, salmon-red erythema.
Table 2. Treatment Resources and Outcome in Relation to Response at Days 1 and 3
Treatment Resource or Outcome
Day 1 Day 3 Delayed Early Response






and Day 1 P Value
Antibiotic treatment duration
Days, total, median (range) 11.5 (6–31) 12 (2–44) .80 11 (2–39) 15.5 (8–44) <.01 12 (8–39) 12 (6–31) .48
≥14 d, total 15/82 (18) 23/130 (18) 1.00 23/170 (14) 11/20 (55) <.01 13/99 (13) 10/71 (14) .86
Days of IV therapy, median (range) 3 (0–21) 3 (0–22) <.01 3 (0–22) 4 (0–22) .13a 3 (1–22) 3 (1–21) <.03a
Antibiotic treatment escalationb
Within 2 d 4/81 (5) 37/129 (29) <.01 27/170 (16) 9/20 (45) <.01a 24/99 (24) 3/71 (4) <.01a
Within 3 d 9/81 (11) 40/127 (32) <.01 32/168 (19) 11/20 (55) <.01a 26/97 (27) 6/71 (9) <.01a
Overall 19/80 (24) 48/122 (39) .02 50/163 (31) 11/19 (60) .02a 34/93 (37) 16/70 (23) .06a
Surgical treatment escalationc 2/80 (3) 3/121 (3) 1.00 2/161 (1) 3/20 (15) .01a 1/91 (1) 1/70 (1) 1.00a
Clinical failured
Deterioration within 2 wk posttreatmente 7/80 (9) 15/117 (13) .37 17/159 (11) 3/18 (17) .43 11/89 (12) 6/70 (9) .44
Readmission within 30 d 4/82 (5) 5/129 (4) .74 8/169 (5) 0/20 (0) 1.00 5/98 (5) 3/71 (4) 1.00
Clinical failure, totald 8/79 (10) 16/116 (14) .44 18/157 (12) 3/18 (17) .46 12/89 (14) 7/70 (10) .50
Resource-demanding coursef 40/79 (51) 66/115 (57) .35 80/156 (51) 15/18 (83) .01 45/87 (52) 35/69 (51) .90
Data are presented as No./evaluable cases (%) unless otherwise specified. Boldface indicates statistical significance (P < .05).
Abbreviation: IV, intravenous.
a Response at day 3 (and delayed response) may have been affected by early treatment escalation, IV therapy, or surgery and is therefore not a true predictor variable regarding these outcomes.
However, increasing the response by such treatment escalation would not have strengthened the statistical association between nonresponse and escalation, but the opposite. Response at
day 3 and delayed response are therefore included as predictor variables, despite the fact that these variables are also based on data not preceding outcomes.
b Addition of an antimicrobial agent or other change giving a regimen with broader antimicrobial spectrum.
c First surgery or more extensive surgery than before performed >1 day after start of in-hospital antibiotic treatment.
d Increase in symptoms or new course of antibiotics between end of therapy and 2 weeks after end of treatment or death or readmission for skin and soft tissue infection within 30 days of
discharge.
e Increase in symptoms or new course of antibiotics between end of therapy and 2 weeks after end of treatment.
f Surgical treatment escalation, antibiotic treatment escalation after 3 days, intravenous treatment >3 days, total treatment duration >14 days, or clinical failure.










or 3. As predictors of nonresponse at day 3, female sex, car-
diovascular disease, higher body mass index, shorter symptom
duration, and cellulitis other than typical erysipelas were iden-
tified. The model-based predicted probabilities of nonresponse
at day 3 ranged from 2% to 42% (median, 8%; interquartile
range, 5%–13%). The apparent AUC for the lasso model was
0.82. Leave-pair-out-cross-validation was used to correct for
optimism, that is, to adjust for possible overestimation of the
predictive ability of the model, reducing the AUC to 0.67.
Sensitivity analysis with replacement of missing response data
identified the same predictors (Supplementary Table 3).
Clinical failure posttreatment could not be predicted by
the baseline factors included in the models of early non-
response; the corresponding lasso model for clinical failure
showed shrinkage to zero for all predictor coefficients and an
AUC of 0.5. The test of joint effect of all predictors showed a
P value of .87, compared with a P value of .008 for the model
of nonresponse at day 3. AUC was 0.5 also if antibiotic or sur-
gical treatment escalation was included in the definition of fail-
ure posttreatment, and the P value then was .37.
Treatment Escalation, Other Resource Use, and Outcome in Relation to
Early Response
Antibiotic treatment escalation was observed in 34% (69/205) of
cases, mostly within 2 days of treatment initiation (Table 2).
Among cases with such early escalation, 90% (37/41) had non-
response at day 1. Most cases with nonresponse at day 1 and
treatment escalation within day 2 had response within day 3,
but not as often as those without escalation (73% [24/33] vs
91% [75/82]; P = .009). Treatment escalation within day 2 was
rarely associated with inappropriate initial therapy (2/40
[5%]) and was common both in cases with confirmed or prob-
able BHS etiology (32/173 [19%]) and other cases (8/39 [27%]).
Long duration of therapy was strongly associated with nonre-
sponse at day 3, but not with nonresponse at day 1 (Table 2).
Surgical treatment escalation was clearly more common in
cases with nonresponse at day 3.
Nonresponse at day 1 and day 3 was not significantly associ-
ated with clinical failure, but nonresponse at day 3 was predic-
tive of a complicated, resource-demanding course (Table 2).
Sensitivity analysis with replacement of missing response data
gave similar results (Supplementary Table 4).
DISCUSSION
The present study gives a detailed description of early re-
sponse dynamics in cellulitis. A majority of patients respond-
ed, clinically or biochemically, the first day after treatment
initiation. Improvement of local inflammation frequently
preceded cessation of lesion spread, a pattern that has been
reported before [9]. The ambiguous relation between ex-
tension of erythema and state of the infection was also dem-
onstrated by the high frequency of residual inflammation
signs at end of treatment. This discrepancy was also evident
in another study reporting resolution of symptoms with
prednisolone treatment without increased risk of relapse
[21]. Interestingly, a combined clinical parameter was more
strongly associated with biochemical parameters than the
FDA-recommended endpoint, which is reduction in lesion
size. Supplementing endpoints relying on erythema size
with other early response parameters may be warranted, as
also discussed previously [22, 23].
Several factors were associated with nonresponse at day 3,
demonstrating that factors other than antibiotic choice and
discordant therapy are important. The impact of comorbidity
has also been demonstrated recently in a large retrospective
study of SSTIs [24]. Additionally, randomized clinical trials
have showed a tendency toward lower early response rates for
patients with high age, high body mass index, and diabetes mel-
litus [25–30]. Prior antibiotic therapy was not a predictor of
early response, probably related to the fact that these patients
were admitted to hospital due to an unsatisfactory response.
Furthermore, we found no association between cellulitis severity
and early nonresponse, in accordance with the findings report-
ed by Talbot et al [31]. In contrast, 2 other studies found some-
what higher rates of early nonresponse among the more severe
cases [24, 30].
Longer duration of symptoms before admission was among
the factors related to early response. This association has, to
our knowledge, previously not been demonstrated. Like the re-
sponse seen after nonantibiotic treatment [10], this may be re-
lated to the natural course of disease; many of those with longer
duration may have passed the maximum intensity of infection
and inflammation.
Impact of treatment choice on early response was demon-
strated as early as the 1930s [11, 12]. However, recent clinical
trials using early clinical response as the primary endpoint
have not demonstrated significant differences between the
drugs tested [26–30, 32, 33], apart from a difference in early re-
sponse found in a study assessing this new outcome measure
retrospectively [25]. In our study, discordant treatment was
infrequent as a result of the predominance of streptococcal
etiology and rare resistance among these microbes. We found
no correlation between discordant treatment and early nonre-
sponse, but the effective sample size was small. However, anti-
biotic choice may be important beyond its relation to in vitro
sensitivity. A recent retrospective study demonstrating an asso-
ciation between early clinical response and higher vancomycin
trough concentration illustrates that drug-specific factors are
also important for early response [34]. The paucity of reports
showing significant associations between initial treatment and
early response underscores that in cellulitis, discordant therapy
or other pharmacological factors are not the major causes of
early failure.
The relatively high frequency of treatment escalation in the
present study is consistent with a recent report [35]. Antibiotic










treatment escalation was often initiated already by day 2 and
was particularly associated with nonresponse at day 1. However,
early treatment escalation among patients with nonresponse
at day 1 was not associated with improved response at day 3,
suggesting that nonresponse at day 1 is not a definite sign of
suboptimal initial therapy. Furthermore, the great majority of
the cases with early nonresponse and treatment escalation
had received appropriate initial therapy. Thus, performing
response assessments very early is of uncertain benefit and
may contribute to the reported common use of broad-spectrum
therapy [5, 6, 35].
In accordance with a retrospective study by Garau et al [24],
we did not find nonresponse at day 3 to be clearly predictive of
clinical failure posttreatment. This is in contrast to what is re-
ported in some clinical trials [26, 28, 29]. Our findings can be
related to a more individualized treatment, such as the longer
duration of treatment in cases with early nonresponse.
We found that factors registered at admission had dis-
criminatory power regarding risk of nonresponse at day 3,
whereas these factors were not useful in prediction of failure
posttreatment. This contrasts with statements postulating that
nonpharmacological baseline factors are mainly responsible
for differences in late outcomes and that early response is
more treatment-specific [13, 23, 36].
Strengths of the study include prospective design and an op-
timized multivariable analysis, using lasso regression, a new
statistical tool giving more reliable models. Another strength
is the representative adult cellulitis population of all ages and
with different comorbidities. However, except for 1 patient,
the population was white and fair-skinned and therefore was
not representative of all populations. Another limitation is the
lack of blinding. Investigators registering clinical response data
were not systematically prohibited from knowing the treatment
ordered. Although the goal and anticipations of the study were
not to demonstrate response differences between treatment reg-
imens, this adds to the importance of including objective
parameters such as CRP reduction. The criteria for early re-
sponse were not directly comparable to the latest regulatory
standards, which recommend ≥20% reduction of lesion size
as the main endpoint [13]. However, lesion area is rarely mea-
sured in everyday clinical work, and the criteria used are, in our
opinion, more compliant with clinical practice. The inclusion of
local inflammation intensity as part of the clinical response
evaluation may have resulted in bias related to the subjective
nature of the parameter. However, our combined response cri-
terion may have given increased validity compared to lesion size
reduction, as discussed above. Due to the observational nature
of the study, the treatment duration was variable, and clinical
cure and failure posttreatment were assessed at different times
after the start of therapy. This variability might have obscured
associations between early and late outcomes and between
baseline factors and late outcomes. The use of telephone
consultation as the main tool in evaluating outcome posttreat-
ment also has weaknesses [37]. Variations in the duration of the
recall periods might represent bias related to outcomes post-
treatment, but somewhat shorter recall time among cases with
inflammation at end of treatment may simply be related to the
fact that these patients were more worried, more immobile, and
more easily reachable.
Overall, the study indicates that nonantibiotic factors with
impact on early treatment response should be considered as
an integrated part of the clinical management of cellulitis.
This may improve individualization of treatment and re-
duce costs and unnecessary rescue therapy. The discriminative
power of early response regarding drug-specific effects needs
further investigation.
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